Bone is one of the most GH-sensitive tissues in the body. Growth hormone deficiency in adults reliably tracks with reduced bone mineral density, and replacement therapy reliably moves it the other way — but only after a characteristic and well-documented early dip. Any compound that touches the GH/IGF-1 axis must be evaluated against this curve, and tesamorelin is no exception.
What makes tesamorelin biologically interesting for bone research is its upstream mechanism. As a 44-amino-acid analogue of human GHRH (1-44) with an N-terminal trans-3-hexenoyl modification that protects it from DPP-4 cleavage, it works on the pituitary GHRH receptor (Ferdinandi 2007). The pituitary still controls the release pattern: pulses, feedback, somatostatin braking. The IGF-1 rise that follows is smoother and more physiologic than what rhGH produces — and that profile turns out to matter at the osteoblast and osteoclast level.
The pivotal Falutz programme (the two phase 3 trials in HIV-associated lipodystrophy) was designed primarily around visceral adipose tissue reduction, but a pre-specified bone substudy was layered on. Falutz et al. (J Clin Endocrinol Metab, 2010) reported BMD by DXA and bone turnover markers over 52 weeks of tesamorelin 2 mg/day SC versus placebo.
| Endpoint | Tesamorelin 2 mg/day | Placebo | Direction |
|---|---|---|---|
| Lumbar spine BMD (52 wk Δ) | No significant decline | No significant change | Bone-sparing |
| Total hip BMD (52 wk Δ) | No significant decline | No significant change | Bone-sparing |
| Osteocalcin (formation) | Increased | Unchanged | Favourable |
| P1NP (formation) | Increased | Unchanged | Favourable |
| CTX (resorption) | Mildly increased | Unchanged | Coupled remodelling |
| IGF-1 | +81% mean rise | No change | Pulsatile, in-range |
The interpretation researchers usually settle on: tesamorelin turned the remodelling unit on — both formation and resorption markers rose, which is what you want for a healthy adaptive cycle — and the net density at the macroscopic DXA level was preserved over a year. In a population (HIV-associated lipodystrophy) that has elevated baseline fracture risk, "preserved" is a meaningful outcome on its own.
The classic adult GH replacement curve, well established by Johannsson, Mauras, Götherström and others, has a distinctive biphasic shape:
That early dip is real, it is reproducible, and it spooks first-time researchers. Tesamorelin's bone-marker profile in Falutz 2010 did not show that early decoupling. Resorption rose a little, formation rose a little more, and DXA stayed flat — not the rhGH dip-then-climb pattern.
The mechanistic explanation usually offered: pulsatile IGF-1 (tesamorelin) preserves the negative feedback brake on resorption, whereas tonically elevated IGF-1 (rhGH) disinhibits osteoclasts early in the cycle before osteoblast activity ramps. Whether this difference matters at the fracture endpoint over 5+ years is still an open research question — but for a 52-week protocol it is a real and measurable advantage.
The Stanley/Grinspoon group at MGH has extended this work into the metabolic dysfunction-associated steatohepatitis (MASH) and NAFLD space, but the bone-marker signal observed in the HIV-lipodystrophy programme is the cleanest dataset we have for BMD specifically. See our related write-up: Tesamorelin in MASH/NAFLD research.
Honest framing: Falutz 2010 was a 52-week study in a specific population (HIV-associated lipodystrophy, mostly male, on antiretrovirals). The bone-sparing signal is encouraging but it is not a fracture-endpoint trial, and it does not extrapolate automatically to:
Researchers running long-horizon protocols typically pair DXA at baseline, 6 months and 12 months with serum P1NP and CTX at the same intervals. That schedule catches the remodelling shift before BMD has time to move.
Every tesamorelin bone-related dataset of consequence used the same dose: 2 mg subcutaneous, once daily, evening administration. Evening dosing aligns the exogenous GHRH pulse with the natural overnight GH window. This is the only dose for which BMD and bone-marker outcomes have been formally reported.
| Vial size | Reconstitution | 2 mg dose draw | Days per vial |
|---|---|---|---|
| 5 mg | 2.5 mL BAC water (2 mg/mL) | 1.0 mL (100 IU) | 2.5 |
| 5 mg | 1.25 mL BAC water (4 mg/mL) | 0.5 mL (50 IU) | 2.5 |
| 10 mg | 2.5 mL BAC water (4 mg/mL) | 0.5 mL (50 IU) | 5 |
| 10 mg | 5 mL BAC water (2 mg/mL) | 1.0 mL (100 IU) | 5 |
For a 12-month bone subset protocol replicating Falutz, the 10 mg vial reconstituted with 2.5 mL BAC water gives the cleanest math: 5 days per vial, 6 vials per month, 72 vials per year. Storage matters in the UAE climate — see our UAE peptide fridge storage guide before ordering bulk.
REVIVE LAB operates a Dubai-based cold-chain facility holding Tesamorelin 5 mg and 10 mg vials in continuous stock. For UAE researchers running 12-month bone protocols, the supply-chain question is as important as the molecule itself — a four-week customs hold mid-protocol invalidates the dataset.
| Emirate | Order cutoff | Delivery window | Service |
|---|---|---|---|
| Dubai | 13:00 GST | Same day, 17:00–21:00 | Same-day cold courier |
| Abu Dhabi | 13:00 GST | Same day evening / next morning | 24h cold courier |
| Sharjah | 15:00 GST | Next morning | 24h cold courier |
| Ajman | 15:00 GST | Next morning | 24h cold courier |
| RAK / Fujairah / UAQ | 13:00 GST | 24–48h | Cold-chain Aramex |
For ongoing 12-month protocols REVIVE offers a standing-order service with monthly auto-shipment from Dubai stock — useful for matching the Falutz dosing cadence without re-ordering each month. Buy Tesamorelin UAE 24h delivery — view stock and pricing. Cross-shop the full catalogue at peptides UAE.
Tesamorelin is the bone-sparing GHRH backbone. Researchers running combined musculoskeletal protocols sometimes layer in:
None of these substitute for tesamorelin's GHRH-receptor specificity, but the bone-formation marker rise observed with tesamorelin alone is what makes the stack research-coherent rather than scattershot. For deeper background see GHK-Cu collagen synthesis research and BPC-157 tendon healing.
REVIVE LAB stocks Tesamorelin 5 mg and 10 mg vials in Dubai and ships next-day across the UAE — same-day to Dubai, 24h to Abu Dhabi and Sharjah, 24–48h to the northern emirates. Cold-chain packaging keeps the lyophilised vials at 2–8°C until handoff.
The Falutz 2010 bone subset showed preserved DXA BMD at lumbar spine and total hip over 52 weeks, with rising bone-formation markers (osteocalcin, P1NP). It is bone-sparing and activates remodelling, but it is not a fracture-trial-validated osteoporosis therapy.
rhGH classically causes an early BMD dip in months 0–6 driven by uncoupled resorption, then recovers and gains over 18–36 months. Tesamorelin's pulsatile mechanism appears to skip that early dip while still activating the formation side of the remodelling unit.
Yes — Abu Dhabi orders placed before 13:00 GST arrive same-day via REVIVE's Dubai-Abu Dhabi cold courier. Sharjah same-day cutoff is 15:00 GST for next-morning arrival.